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Abstract
Background
Infectious mononucleosis (IM) is a common adverse presentation of primary infection with
Epstein-Barr virus (EBV) in adolescence and later, but is rarely recognized in early child-
hood where primary EBV infection commonly occurs. It is not known what triggers IM, and
also not why IM risk upon primary EBV infection (IM attack rate) seemingly varies between
children and adolescents. IM symptoms may be severe and persist for a long time. IM also
markedly elevates the risk of Hodgkin lymphoma and multiple sclerosis for unknown rea-
sons. The way IM occurrence depends on age and sex is incompletely described and hard
to interpret etiologically, because it depends on three quantities that are not readily observ-
able: the prevalence of EBV-nave persons, the hazard rate of seroconverting and the attack
rate, i.e. the fraction of primary EBV infections that is accompanied by IM. We therefore
aimed to provide these quantities indirectly, to obtain epidemiologically interpretable mea-
sures of the dynamics of IM occurrence to provide etiological clues.
Methods and findings
We used joint modeling of EBV prevalence and IM occurrence data to provide detailed sex-
and age-specific EBV infection rates and IM attack rates and derivatives thereof for a target
population of all Danes age 0–29 years in 2006–2011. We demonstrate for the first time that
IM attack rates increase dramatically rather precisely in conjunction to typical ages of
puberty onset. The shape of the seroconversion hazard rate for children and teenagers con-
firmed a priori expectations and underlined the importance of what happens at age 0–2
years. The cumulative risk of IM before age 30 years was 13.3% for males and 22.4% for
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females. IM is likely to become more common through delaying EBV infection in years to
come.
Conclusions
The change in attack rate at typical ages of puberty onset suggests that the immunologic
response to EBV drastically changes over a relatively short age-span. We speculate that
these changes are an integrated part of normal sexual maturation. Our findings may inform
further etiologic research into EBV-related diseases and vaccine design. Our methodology
is applicable to the epidemiological study of any infectious agent that establishes a persis-
tent infection in the host and the sequelae thereof.
Introduction
Most people are infected with Epstein-Barr virus (EBV) during childhood or adolescence,
resulting in a persistent, mostly latent EBV infection. The primary EBV infection often mani-
fests as infectious mononucleosis (IM), especially in adolescence [1,2]. Globally EBV is causally
linked to nearly 200000 incident cancers and 18000 deaths from multiple sclerosis annually
[3,4], with IM elevating the risk of Hodgkin lymphoma and multiple sclerosis for unknown
reasons [5–7]. Functions of EBV antibody levels as predictors of disease risk is an active field
of research, see [8] and references therein.
At the same time it is unclear why upon primary EBV infection some individuals present
with IM, while others do not [9]. Disease severity and duration correlate much better with e.g.
CD8+ cell counts than with the viral kinetics itself and the expansion of the CD8+ cell count is
controlled in asymptomatic EBV infection despite virus loads similar to those experienced in
symptomatic EBV infection [1,2,10–14]. Hence current understanding suggests that IM is
caused by overreaction by the immune system, rather than EBV infection per se (viremia or B-
cell expansion). There now seems to be broad agreement that a massive expansion of the num-
ber of EBV-specific CD8+ cells is a characteristic of IM, while changes in the proportions of
other cell populations seem less well-established [1,2,10–13,15,16]. Clinically, IM is typically
characterized by fever, pharyngitis, lymphadenopathy and fatigue. The IM symptoms are
believed to be caused mostly, if not entirely by the exaggerated CD8+ response [2,15,16]. Pre-
sumably IM is the same disease in teenagers as in children, because the immunological
response to EBV infection is recognizably the same [10,17].
The way IM occurrence depends on age and sex is incompletely described and hard to
interpret etiologically. The age distribution of incident IM is dominated by a distinct peak in
the middle of the teenage years [18,19]. However, as an etiological clue this is not particularly
useful because the depicted rate is not really a rate, i.e. a number of IM cases divided by the
time at risk of those who have not seroconverted. Rather it is a product of the prevalence of
EBV-nave persons, the hazard rate of seroconverting and the attack rate, i.e. the fraction of pri-
mary EBV infections that is accompanied by IM. Attack rates have only been estimated in
young adults [20–23], and estimated sero-conversion rates are practically non-existent too.
It would therefore be valuable to devise and fit a mathematically coherent model, projecting
what would be the age- and sex-specific seroconversion rate and attack rate in a hypothetical
population where the observed age- and sex-specific EBV-prevalence and IM occurrence in
the target population apply. Such a model could quantify e.g. how much of the IM teenage
peak is due to changed behavior (changing hazard of seroconversion), and how much to
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changed susceptibility to IM (changing attack rate) in teenagers compared with pre-
adolescents.
As proof of concept we therefore fitted such a model based on a few large data sets, with
Danes age 0–29 years in 2006–2011 as our target population.
Methods
Materials
We used the Danish Civil Registration System [24] to follow-up persons while resident in Den-
mark in 2006–2011 and of age 0–29 years for incident IM in NPR. Incident IM in the Danish
National Patient Register (NPR) [25] for a person was defined as the first hospital contact with
IM as main, secondary, or underlying diagnosis, classified as code 075� in ICD-8 and code
B27� in ICD-10 [19,26].
In 2010 and 2011 the Danish Blood Donor Study (DBDS) [27] asked participants:”Were
you ever told by a doctor that you had infectious mononucleosis” and if so–”At what age?”.
The study base of IM cases from DBDS was defined as DBDS participants who either 1) had
reported IM in 2006–2011 at age 0–29 years or 2) had reported IM at age 0–14 years or 3) were
IM cases in NPR at age 0–29 years at time of DBDS interview and born in 1976+. We then
searched for these persons as IM cases in the NPR. Criterion 2) ensures that we can estimate
IM hospitalization rates at age 0–17 years (donors must be 18+ years at interview) and crite-
rion 3) makes a hospital diagnosis of IM equally valid as one proclaimed by a general
practitioner.
EBV test results recorded in the Laboratory Information Management System of Statens
Serum Institut, Copenhagen, Denmark were mapped into positive and negative results as in
Rostgaard et al [19]. The first result was retrieved for all persons serologically tested for pri-
mary EBV infection from January 2005 to May 2011. The serological test was based on mea-
surements of IgG antibody titers to EBV nuclear antigen (EBNA) and IgG and IgM antibody
titers to EBV capsid antigen (VCA). All measurements were performed using enzyme-linked
immunosorbent assay (Biotest, BioNordika, Herlev, Denmark). Each test result was coded as
1)”prior infection” if EBNA was positive, 2)”positive” if VCA IgG or VCA IgM were”positive”
or”weak” while at the same time EBNA was”negative” or”weak” and 3)”negative” if VCA IgG,
VCA IgM and EBNA were all”negative”. Any test result that did not match any of these three
disjoint criteria was discarded [19]. The test results were obtained from analyzing test samples
sent from hospitals and general practitioners from all parts of Denmark, but predominantly
from Sealand [19].
For convenience we used a discrete survival model and hence lumped age into 61-day inter-
vals denoted by a = 0,1,2,. . .,179, a = 180� 30 years. The data were aggregated accordingly. In
order to obey a data discretionary rule of at least 5 observations in a cell, the data were sorted
by type, sex and age and cells then aggregated on a running basis to fulfil this criterion, the age
interval denoted by the rounded mean of a. The data were used in that form and are available
in S1 Data. We did not use data from the first year of life due to the maternally-derived EBV
sero-positivity shortly after birth [17,28].
Statistical methods
The statistical framework for this paper is a Markov model with the following states (see pages
1–25 and 457–475 in [29]):
0: EBV negative
1: EBV positive, no history of IM
2: EBV positive, a history of IM
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We describe the dynamics of the system only in terms of age a and sex s. Let S(a,s) be the
sex- and age-specific probability of being in state 0. Let the probability of moving from state 0
to state 1 or state 2 be f1(a,s) and f2(a,s), respectively. These are expressed in terms of the proba-
bility of being at risk in state 0, S(a-1,s), the probability of moving out of state 0 if in that state,
(1+exp(-εs(a)))-1 and the probability of presenting with IM upon seroconversion, P(a,s) = (1
+exp(-ϊs(a)))-1, i.e. f1(a,s) = (1-P(a,s))(1+exp(-εs(a)))-1S(a-1,s) and f2(a,s) = P(a,s)(1+exp
(-εs(a)))-1S(a-1,s). Let the probability of hospitalized IM among IM cases in DBDS be P(a,s) =
(1+exp(-νs(a)))-1. Let p0, p1 and p2 be shorthand for the probability of being in state 0, 1, and
2. Similarly let imfrac and hospfrac be shorthand for the probability of IM upon seroconver-
sion and hospitalization upon having IM.
The model was fitted using SAS proc HPNLMOD. The functions εs(a), and νs(a) were mod-
eled as fractional polynomials of degree 4 and 2, with power sets (-1,0,0.5,1) and (2,1), respec-
tively (see pages 77–98 in [30]). Thus νs(a) was a second degree polynomial in a. These
fractional polynomials sufficed to provide an adequate fit, according to goodness-of-fit tests
and inspection of residuals. Preliminary analyses revealed that ϊs(a) were complicated func-
tions, requiring 8–12 degrees of freedom for an adequate fit. The functions ϊs(a) were modeled
as restricted cubic splines (see pages 20–24 in [31]). The knots for the splines were common
for the sexes and at the outset placed at deciles of the number of IM events in NPR. We then
added knots at the 2.5, 5 and 7.5 percentile to obtain a satisfactory fit also in a region with few
IM cases but much change in seroconversion rates. imfrac did not look as expected in the tail
and very different between the sexes. We considered this to be a consequence of model uncer-
tainty regarding the post-teenage years in combination with the notorious wigglyness of high-
dimensional splines. To remedy this we therefore removed the two top knots, retaining an ade-
quate model fit according to goodness-of-fit tests. Finally we fixed ϊs(a) to be constant above
the new top knot, at the cost of an increase in deviance of 2.5–3 in each sex in order to remove
unrealistic decreasing trends above the top knot.
The link between model and data was provided by the following contributions to the model
log-likelihood (ll):
for EBV prevalence data with POS positives among N tested:
ll = POS�log(p1+p2)+(N-POS)�log(p0)
for DBDS data with POS hospitalized among N IM cases:
ll = POS�log(hospfrac)+(N-POS)�log(1-hospfrac)
for NPR data with EVENTS IM cases in PYRS person-years at risk:
ll = EVENTS�log(him)-him�PYRS
where
him = 6�imfrac/((1+exp(-))�(1+exp(-ν)))�p0/(p0+p1)/0.9
The construction of most of the graphs in Fig 1 from quantities described here is immedi-
ate. The seroconversion hazard rate in Fig 1C is 6/(1+exp(-εs(a))) events per person-year.
Assumptions
We assume that all persons start in state 0 at birth, i.e. we ignore that EBV can pass across the
placenta during pregnancy [32]. Death, emigration etc is considered non-informative censor-
ing. The incubation time of around 42 days [12] from EBV infection to possibly overt IM is
ignored. Since they are few, and not directly identifiable, we have not created a special state for
persons who will remain EBV-negative [33,34], e.g. due to lack of the EBV receptor CD21 on
B-cells [33]. Similarly, states 1 and 2 are absorbing, so we do not allow alternation between sus-
ceptible and non-susceptible states, suggested as possible by Helminen et al. [34], nor do we
allow multiple EBV infections where the first did not cause IM, but one of the later did, i.e. we
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assume that once a latent EBV infection is established you cannot get IM caused by EBV. We
assume that a person can have IM only once, e.g. that a person cannot have a second IM
caused by e.g. cytomegalovirus. The data on IM incidence will usually be exaggerated due to
lack of proper laboratory confirmation of EBV involvement in IM-like disease symptoms. Part
of the problem is that only 90% of true IM is caused by EBV [35], that is the 0.9 in the expres-
sion for ’him’ above.
Miscellanea
The risk of getting IM before age 30 years was calculated as 1-exp(-H(a)), where H(a) is the
cumulative population IM incidence rate at age a, i.e. the integral of the curves shown in Fig
1F.
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Fig 1. Model predictions with 95% confidence limits by age for females (red) and males (blue). The model was created from jointly fitting C, D, E; the results in B, F,
G and H were derived from this. The flat attack rate above age 18 years in subgraph D is a self-imposed model constraint, see Methods. Subgraph A is the EBV-
seroprevalence by age in Denmark in 2006–2011. The dotted line was predicted from the model.
https://doi.org/10.1371/journal.pone.0226436.g001
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Estimates and confidence limits as presented in the figures were calculated from the predict
logic of SAS proc HPNLMOD. In these calculations the leading coefficient of νs(a) was fixed to
avoid inexplicable variance inflation in Fig 1H. The variance estimates in the other graphs
were essentially unaltered by this fix.
All statistical calculations were performed using SAS statistical software (SAS Institute,
Cary, NC. version 9.4).
The study was approved by the institutional review board of Statens Serum Institut and the
Scientific Ethics Committee Central Denmark (M2009237). As such it adheres to Danish law,
including the European Union General Data Protection Regulation and is conducted accord-
ing to the principles expressed in the Declaration of Helsinki. Written informed consent was
obtained at enrollment into the DBDS[27], while specific informed consent for use of the
other (register) data sources in this study was not needed according to Danish law.
Results
All Danes age 0–29 years resident in Denmark somewhen during calendar years 2006–2011, in
all 2,485,292 persons, were followed up in the same age and period range for a hospital contact
with an IM diagnosis during 11,376,713 person-years of follow-up, yielding 4703 incidents of
hospitalized IM. 2487 blood donors from The Danish Blood Donor Study, who had self-
reported IM or had been hospitalized with IM under the right conditions (age and period, see
Methods) were assessed for hospitalized IM to yield the fraction of hospitalized IM among IM
cases (185/2487 = 7% of IM cases). 6145 persons tested for EBV antibodies at Statens Serum
Institut at age 0–29 years during calendar years 2006–2011 yielded 3513 (57%) infected with
EBV. The three statistically sufficient data sets for these three outcomes and the only data sets
used for our analyses are available in S1 Data, labelled in the type variable as NPR, DBDS and
EBVPREV, respectively. The results of our modeling are a set of age- and sex-specific predic-
tions, presented in Fig 1A–1H, and the same predictions in a slightly aggregated life-table for-
mat in Table 1, with columns labelled B to H. Throughout we shall only refer to the figures, the
reader may consult the relevant columns of the table instead.
The EBV prevalence in our data set was generally lower than in older unselected Danish
data [36,37], but otherwise similarly distributed (Fig 1A). Sex-specific corresponding propor-
tions of EBV nave individuals are shown in Fig 1B.
Both sexes experienced peaks in seroconversion rate as infants and as young adults (Fig
1C). The seroconversion rates for boys and girls were similar on the left side of the nadir in
seroconversion rate, but girls had the highest rate to the right of the nadir (Fig 1C). The sero-
conversion rate peaked at age 17.2 years in females and at age 17.5 years in males.
The IM attack rate rose from practically nothing in children aged 0–2 years to represent a
very common phenomenon in teenagers (Fig 1D). A peak in attack rate appeared in teenage
years, and was especially pronounced among girls. The attack rate was higher in females than
males throughout the teenage years. The attack rate peaked at age 16.3 years in girls and at age
17.3 years in boys and likewise the local minimum in attack rate to the left of the peak occurred
at age 11.0 years in boys and at age 10.5 years in girls (Fig 1D).
For all ages the fraction of hospitalized IM cases was larger for males than for females. The
fraction of IM cases becoming hospitalized was unimodal and typically low with a minimum
of 6% at age 18.3 years and 4% at age 21.8 years for males and females, respectively (Fig 1E).
Fig 1F, 1G and 1H contain what we call population rates. The denominator in these rates is
time at risk for the entire population, not just the subpopulation of EBV nave.
The IM population hazard rate is the product of the seroconversion population hazard rate
and the attack rate. The location and shape of the IM population hazard rate peak in teenage
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years (Fig 1F) was essentially determined by the attack rate (Fig 1D), which varied considerably
more in this age span than the seroconversion population hazard rate (Fig 1G).
The combination of information in Fig 1C and 1D revealed several things. For children
age 0–2 years the attack rate was low and the seroconversion rate high, as a priori expected
from prevalence and rate data. For 3–12 years old children the IM population hazard rate
was kept low mainly by a small seroconversion rate, since the attack rate, relatively speaking
increased substantially compared to the attack rate in 0–2 years old children. Comparing
children age 4 to 5 years (the nadir of seroconversion) with teenagers age 16 to 17 years (the
peak in IM attack rate) the seroconversion rate was lower by a factor of 6 to 8, while the cor-
responding attack rate was lower by a factor of 6 to 10. Accordingly, the low incidence of
IM in 3–12 years old children was roughly equally due to low attack rate and low serocon-
version rate.
Table 1. Model predictions by age and sex. Prevalent cases per 100,000 cases (B), events per 100,000 person-years (C,F,G,H) and probability x 100,000 (D,E). B: EBV
naive, C: seroconversion hazard rate, D: attack rate, E: fraction of hospitalized IM cases, F: IM population hazard rate, G: seroconversion population hazard rate and H:
hospitalized IM population hazard rate. C-H are averages within the age group, B is the maximum within the age group, i.e. who were EBV-naïve at exact age 1,2,. . .Refer
to Fig 1 and methods for further details.
B C D E F G H
age m f m f m f m f m f m f m f
1 91520 82765 24843 20157 261 420 49106 27478 52 60 20646 15698 25 17
2 73260 70853 7174 4502 1301 1578 41541 23364 63 49 5138 3145 26 11
3 69067 68204 2792 2208 4962 4849 34775 19871 100 78 1912 1495 35 15
4 67340 66798 1832 1802 7830 7494 28953 16939 107 100 1228 1197 31 17
5 66158 65609 1643 1903 7713 7890 24088 14497 93 109 1083 1243 22 16
6 65077 64340 1757 2287 9101 9138 20111 12473 115 149 1140 1464 23 18
7 63917 62827 2066 2917 9419 9007 16907 10802 138 182 1316 1820 23 20
8 62565 60938 2544 3795 8049 7406 14351 9423 141 188 1585 2293 20 18
9 60932 58561 3185 4921 6331 5798 12326 8287 135 183 1929 2848 17 15
10 58945 55619 3975 6272 5172 5008 10729 7351 133 191 2325 3433 14 14
11 56558 52092 4887 7786 4995 5579 9477 6581 152 247 2735 3974 14 16
12 53762 48038 5869 9368 6501 9274 8502 5947 226 455 3115 4395 19 27
13 50599 43594 6850 10893 12119 22756 7751 5426 462 1177 3419 4642 36 63
14 47154 38961 7747 12220 23511 47058 7186 5000 946 2463 3614 4712 68 123
15 43558 34368 8470 13220 33900 63392 6776 4655 1386 3240 3680 4602 94 151
16 39957 30029 8944 13790 40552 70366 6501 4378 1625 3377 3608 4318 106 148
17 36495 26105 9118 13876 44644 62818 6347 4160 1692 2714 3411 3883 107 113
18 33291 22694 8973 13474 38086 58313 6306 3994 1317 2176 3106 3357 83 87
19 30431 19826 8525 12633 36242 57974 6377 3875 1100 1810 2732 2810 70 70
20 27955 17481 7821 11446 36242 57974 6562 3800 939 1475 2331 2290 62 56
21 25875 15608 6932 10026 36242 57974 6871 3765 779 1175 1934 1824 53 44
22 24172 14143 5939 8498 36242 57974 7320 3770 630 917 1564 1423 46 35
23 22810 13017 4921 6973 36242 57974 7932 3816 497 702 1235 1089 39 27
24 21747 12166 3946 5545 36242 57974 8738 3902 383 527 951 819 33 21
25 20935 11532 3065 4276 36242 57974 9781 4033 288 389 716 604 28 16
26 20330 11070 2306 3201 36242 57974 11118 4212 212 282 526 437 23 12
27 19888 10737 1683 2327 36242 57974 12820 4444 152 200 377 310 19 9
28 19573 10503 1193 1645 36242 57974 14976 4738 106 139 264 215 16 7
29 19354 10341 821 1131 36242 57974 17692 5104 72 94 180 146 13 5
https://doi.org/10.1371/journal.pone.0226436.t001
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Discussion
Our analyses for the first time provide detailed and compelling evidence that the accumulation
of IM among adolescents, a characteristic of western industrialized countries, reflects age-
dependent variations both in IM attack rates and EBV seroconversion hazard rates.
Both early childhood and adolescence are age-periods characterized by social behaviors
involving the exchange of saliva, the primary route for EBV transmission, e.g. through sharing
of toys and utensils in early childhood and through kissing in adolescence and early adulthood
[38]. Deep kissing as the main route of EBV transmission in adolescence and beyond is well
established [9], while the evidence for sharing of toys and utensils in early childhood as an
important route of EBV transmission is weaker and indirect, e.g. a marked reduction in IM
risk for each additional sibling, especially when the age-differential is small[19,39], presumably
due to pre-teenage EBV infection.
To become infected, EBV nave individuals must interact with EBV-positive infectious indi-
viduals. Consequently, spreading of EBV depends on patterns of interaction between EBV-sus-
ceptible and EBV-infectious individuals and the likelihood of EBV transmission and infection
at such encounters. In early childhood when the vast majority of individuals are still EBV-
nave, EBV will spread rapidly because many encounters between these EBV-nave children and
EBV-positive parents/adults/same age children has the potential to create an EBV infection in
the EBV-nave child.
The steep decline in seroconversion hazard rates between ages 2 and 5 years is dispropor-
tionate to the decrease in EBV-susceptible individuals. Therefore, rather than the gradual
reduction in proportions of susceptible and possibly also acutely infected (infectious) individu-
als, the decreasing risk of EBV-infection and the plateauing sero-prevalence likely reflect age-
related changes in behavior associated with lower risk of EBV transmission from both other
children and parents/adults.
The second wave of EBV infection occurred in adolescence through early adulthood, with
the highest EBV hazard rates occurring at slightly younger ages in females than in males. This
may reflect earlier puberty in girls than in boys, and the typical age-disparity in female-male
relationships with girls tending to partner with older boys [40]. Because of the age-dependent
increase in EBV-sero-positivity, girls at any age would tend to engage with boys more likely to
be EBV infected than boys their own age, whereas the opposite would be true for boys who
would engage with younger girls, less likely to be EBV infected than girls their own age.
Although of waning relevance in Western societies we also speculate that girls more often than
boys expose themselves as caretakers to siblings and other children of age 0–3 years, whom we
have identified as risk factors for IM and thus primary EBV infection [19]. All these interaction
patterns would accelerate seroconversion in the female population and decelerate it in the
male population.
The shape of the attack rate essentially complies with the dogma of IM being more frequent
and severe the older the age at seroconversion [41–43] yielding something close to a monotone
increase by age (Fig 1D).
The mechanisms underlying the age-dependent variation in IM attack rate have remained
elusive, but proposed explanations include corresponding variations in mode and dose of
infection and in host immune response [2,11,15,44]. The host immune response may vary by
age for at least two reasons: 1) NK cell responses may assume greater importance, and perhaps
be more effective, in combating virus infections early in life [15], and/or 2) adolescents
infected with EBV may recruit large numbers of cross-reactive memory T cells previously cre-
ated in response to other viral infections, which may more easily be activated but be less effi-
cient in controlling the infection than primary responses from recruited nave T cells [44].
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However, in light of the very rapid change in IM attack rate, we do not consider cross-reactiv-
ity of memory T cells to be a likely major contributor to this change. Similarly Balfour et al.
found no evidence of influenza-EBV dual specific CD8+ T cells in their study cohort to sup-
port this explanation [9,11]. Likewise both simulations [44] and observational studies [2,12,45]
suggest that the initial viral load, and hence dose or mode of delivery is of little importance for
IM risk.
Our results, including the fact that the adolescent attack rate peak among females occurs at
a slightly younger age than the corresponding peak in males, instead point to IM susceptibility
as somehow being subject to mechanisms that involve growth and/or sex hormones whose lev-
els change as part of sexual maturation. In this regard, it is noteworthy that both estrogen and
androgens are known to influence immune responses via epigenetic mechanisms, see [46] and
references therein.
Strengths and weaknesses
We believe the serological data on prevalent EBV status to be accurate. They are based on
enzyme-linked immunosorbent assays, which can perform very similarly to the gold standard
of immunofluorescence arrays [1,47–49]. However, the tested patients were not randomly
sampled, and as such may yield a biased representation of the age- and sex-specific EBV-preva-
lence in our population. Specifically, most persons in our sample were presumably tested in
order to determine whether symptoms similar to IM could be due to an acute EBV infection.
Furthermore, we suspect that many of the samples were sent for serological testing due to atyp-
ical IM symptoms or results of a quick but unreliable IM test, that the general practitioner did
not trust. As such one would expect to sample too many recently EBV-infected persons. On
the other hand, comparison with older unselected Danish data sets suggest, if anything, that
we have too few EBV-infected persons in our sample at a given age.
Secular changes, specifically the Danish society becoming more affluent would tend to
lower the age-specific sero-prevalence in our material compared to older Danish materials
[1,50]. This could explain the discrepancy, and recent examples of such trends in other West-
ern countries exist [11,41]. In Denmark the gradual increase in childcare attendance from
around 1965 to 2000 [51] would tend to work in the opposite direction, but the effect is proba-
bly modest since the most common type of childcare for children age 0–2 years is by daycare
mothers, i.e. caretakers taking care of only a few children. Currently only a third of a genera-
tion of children age 0–2 years attends an institution (creche, kindergarten or integrated institu-
tion), see {http://statistikbanken.dk}{statistikbanken.dk}.
Altogether, we believe that our estimated seroconversion rates are sufficiently accurate to
model the essential seroconversion dynamics in our target population.
For the purpose of attributing causes for IM in different age groups, it seems more impor-
tant to get the ratios of age-specific attack rates within sexes, rather than the exact level, correct.
We see no reason why our data or modeling should be noticeably biased with respect to assess-
ing ratios of age-specific attack rates within sexes. Furthermore, our estimated attack rates
around age 20 years are compatible with earlier detailed longitudinal studies on university stu-
dents and army recruits [20–22], and do not de facto become 100% at any age as would be the
sign of a severe upwardly biased ascertainment of incident IM.
We believe the variation in the fraction of IM cases hospitalized to be a natural screening
phenomenon. Specifically, we believe that general practitioners expect IM symptoms in teen-
agers to be caused by IM and therefore do not admit such cases to hospital, while the more
unexpected and for children more non-specific IM symptoms [52–55] would cause general
practitioners to admit a patient to hospital for further investigation more often. We do not
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know why the fraction of hospitalized IM cases is higher in boys than in girls; if anything, girls
seem on average to have the most vigorous immune response as measured by EBV antibody
titers [56–58]. Furthermore, there seemingly is no age gradient (age 6–17 years) in EBV anti-
body titers [58], supporting the view that the bathtub shaped curves are a screening phenome-
non, rather than due to physiology.
The cumulative risk of IM before age 30 years was 13.3% for males and 22.4% for females.
This estimate is quite high compared to other estimates (� 5% with much variation) (Rost-
gaard et al. [26] and Table 5 in Hjalgrim [59]). We have no immediate explanation for this.
However, we do not consider it surprising to have a substantially larger ’’lifetime’’ risk of IM in
our target population than in other older and less affluent settings referred to above. E.g. the
percentage of 15–17 year old EBV nave Americans increased from 22 to 31 over just 6 years
(Table 2 in Balfour et al. [1]), which all else equal should increase the occurrence of IM in that
age span a factor 31/22 = 1.41. If the percentage of EBV nave at the IM teenage peak was much
lower in the past a change in the occurrence of IM of a factor 3 or 4 is certainly possible. Fur-
thermore the blood donors in our study being on average better educated and wealthier than
non-donors [60] would suggest them to be recruited from affluent population strata and as
such more prone to late EBV infection and thus presenting with IM than the general
population.
Conclusion
Studies to predict the possible benefit of a specific EBV vaccine was one of five priorities out-
lined at an EBV-vaccine meeting organized by the US National Institutes of Health in 2011
[61]. The present study provides for the first time some of the knowledge needed for that pur-
pose by precisely displaying at what age persons seroconvert and when it has consequences in
terms of IM, with all the sequelae that goes with that [3–7].
Mathematically the pair of descriptors (EBV hazard rate, IM attack rate) has the advantage
compared with (EBV prevalence, IM incidence) of being more”local” in time, and therefore
better suited to generation of causal interpretations and hypotheses, as causal mechanisms
work locally in time, i.e. causes continually transmit their effects [62]. We think our study vin-
dicates this point of view.
Methodologically we found it relatively easy to transform prevalence data into mathemati-
cally coherent and equivalent forms, primarily smooth hazard functions. We found these
more informative than the raw prevalence data for, in this case, the dynamics of EBV infection.
Our prevalence data were very detailed regarding age, but usually much cruder data would suf-
fice for obtaining a model-based smooth hazard function. We believe that this type of analysis
would be helpful in many future studies of the epidemiology of specific persistent infections.
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